Risk factors for hypogammaglobulinemia in chronic lymphocytic leukemia patients treated with anti-CD20 monoclonal antibody-based therapies
| Autor: | Sameer A. Parikh, Caitlin M.G. McNulty, Brian Kabat, Avni Y. Joshi, Pragya Shrestha, Melissa R. Snyder, Susan L. Slager, Emasenyie Isikwei, Kari G. Rabe |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Histology Hematology biology business.industry Proportional hazards model medicine.drug_class Chronic lymphocytic leukemia Monoclonal antibody medicine.disease Immunoglobulin G Pathology and Forensic Medicine Hypogammaglobulinemia 03 medical and health sciences 0302 clinical medicine hemic and lymphatic diseases 030220 oncology & carcinogenesis Internal medicine biology.protein Medicine Antibody business Complication 030215 immunology |
| Zdroj: | Journal of Hematopathology. 13:221-229 |
| ISSN: | 1865-5785 1868-9256 |
| DOI: | 10.1007/s12308-020-00417-5 |
| Popis: | Hypogammaglobinemia is a well-recognized complication in chronic lymphocytic leukemia (CLL); however, the risk factors that lead to this complication after treatment with anti-CD20 monoclonal antibodies are not well understood. Using the Mayo Clinic CLL database, a retrospective chart review was conducted on patients enrolled between January 1995 and September 2017 who had pre- and post-treatment immunoglobulin values. The relationship between immunoglobulin values prior to treatment as well as post-treatment with clinical variables and overall survival (OS) was evaluated. Hypogammaglobinemia was defined as serum immunoglobulin G (IgG) levels |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink